Novavax Inc (NVAX.OQ)
22 Feb 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|64||2011||Independent Chairman of the Board|
|68||2017||President, Chief Executive Officer, Interim Chief Financial Officer, Director|
|63||2016||President, Research and Development|
|52||2014||Senior Vice President, General Counsel, Corporate Secretary|
|57||2014||Senior Vice President - Commercial Operations|
- BRIEF-Novavax Inc Files For Mixed Shelf Of Up To $200 Mln
- BRIEF-Novavax Files Prospectus Supplement Related To Issuance, Sale Of Up To $75 Mln Of Common Stock
- BRIEF-Novavax Continues Phase 3 Trial Of RSV F Vaccine For Infants Via Maternal Immunization
- BRIEF-Novavax CEO Stanley Erck reports open market purchase of 100,000 co's common shares
- BRIEF-Novavax Q3 loss per share $0.15